Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20. Also Read: Abbott ...
We recently compiled a list of the Jim Cramer is Talking About These 14 Stocks Before Earnings. In this article, we are going ...
2d
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback